Rare diseases
Investigational molecules
Locations
1801 Augustine Cut Off, 19803-4404, United States
Incyte Corp. funds research across diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary mediastinal large B-cell lymphoma, and other hematologic malignancies, with additional interest in myelofibrosis, myeloproliferative neoplasms, and myelodysplastic and overlap syndromes. Its portfolio also includes studies in autoimmune hemolytic anemia, immune-mediated thrombocytopenia, and anaemia associated with myelofibrosis.
Research also extends to treatment settings involving relapsed or refractory disease and advanced blood cancers requiring ongoing therapeutic options.
Incyte Corp. runs clinical trials in conditions such as Hidradenitis, Vitiligo, Neurodermatitis, Chronic graft versus host disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo
AustriaLong-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials
AustriaRandomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients
AustriaINCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
AustriaA study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia
FranceA Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein
BelgiumStudy of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments
BelgiumStudy on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients
AustriaStudy on the Effectiveness of INCB000928 for Patients with Fibrodysplasia Ossificans Progressiva
FranceStudy for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments
PolandContinued Treatment Study for Patients with Blood Cancers Using Tafasitamab
HungaryStudy of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
